Al Novas

Chief Operating and Financial Officer - Wolfe, LLC

[Al Novas @AlNovas]

@Pinklady AdComm is the worst and has hurt this country.

[Al Novas @AlNovas]

@luciman @Pinklady That may explain today’s separation, but not Friday’s when all ETFs were down (i.e., the S&P 500 was down 2.2%). Just look at the AH tonight.

I hope $BNTX is included…

[Al Novas @AlNovas]

@GreenTsunami $BNTX Also, look at BNTX’s superior and outstanding balance sheet, free cash flow, higher earnings, plus consider the upcoming intellectual property lawsuit vs the US government and the billion(s)? in potential unrec... https://t.co/rr8Q4mkWLN

[Al Novas @AlNovas]

@Pinklady True. We have the EMA approval. Reuters speculated on Thursday EU approval should have occurred this past Friday. Maybe in the morning…

“While final approval is up to the European Commission, it typically follows EMA rec... https://t.co/2kPrrSIf9B

[Al Novas @AlNovas]

@Pinklady $BNTX $PFE And 100% market share in Europe as well as of Thursday, which has not received as much attention due to Omicron…

[Al Novas @AlNovas]

@Pinklady @victory_500 Many public agencies required that employees get vaccinated or face dismissal. Fifty unvaccinated employees of the police and border guard agency are suing their agency over this policy and on Thursday a cour... https://t.co/SxBiU0iURO

[Al Novas @AlNovas]

@Pinklady @victory_500 As the latest Covid-19 wave flares up, countries are starting to take a tougher stance toward those who haven’t been vaccinated.

From sending those without shots into lockdown, to forcing them to pay thei... https://t.co/Rd447lwiAb

[Al Novas @AlNovas]

@BionTechPfizer https://t.co/co7dlIaz1P

[Al Novas @AlNovas]

@betachaser This book confirmed the quality of BNTX and its CEO/CMO. However, BNTX is turning into a stock untethered to fundamentals and comparisons to peers.

A Shot to Save the World by Gregory Zuckerman. https://t.co/viEfyMqRhP

[Al Novas @AlNovas]

@Aubyn Thank you.

[Al Novas @AlNovas]

@mason890 @mby7 Plus their recent acquisition into precision antibodies via PhagoMed.

But today’s price action, especially vs MRNA is inexplicable.

• 100% EPS greater vs MRNA
• +45% greater revenue vs MRNA
• Will meet all avail... https://t.co/bn0LxsV8uu

[Al Novas @AlNovas]

@Pinklady 2/2 “We will not rest until our vaccine is available to anyone who needs it, and we are working hard to ensure our vaccine is available in low-income countries with approximately 10 per cent of our 2021 volume and signifi... https://t.co/w6ItiQSopb

[Al Novas @AlNovas]

@Pinklady Here you go as much as will fit: 1/2
“Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of f... https://t.co/jDuqQBb0Ew

[Al Novas @AlNovas]

@mason890 This is still $100 below the share price when we announced earnings three months ago, and our earnings prospects and addressable market has only gone up. In addition, compare the price action to MRNA during the same thre... https://t.co/kPsUcwm80i

[Al Novas @AlNovas]

@BionTechPfizer as of right now and I do not know of Moderna applying for 5 to 11. And the FDA is slow walking the 12 - 17 year old application from Moderna. Plus Moderna has the additional baggage of a worse reactogenicity vs BNTX... https://t.co/fwN1j531CM

[Al Novas @AlNovas]

@BionTechPfizer I’m hoping Russia’s favorable relations with Germany may ease such a transaction…

[Al Novas @AlNovas]

@Pinklady @victory_500 France’s health agency wants more details on the effects of Moderna’s Covid vaccine on younger people amid concerns about potential side effects, Dominique Le Guludec, who heads the agency, told Le Journal du... https://t.co/cldgFOXUK2

[Al Novas @AlNovas]

@betachaser There will be a compounding effect when you add on boosters for the world’s population under 18 as those vaccinated with BNTX/PFE while MRNA is blocked, since parents will stay with BNTX.

[Al Novas @AlNovas]

@betachaser They have two different analysts on these two names. The MRNA analyst is more of a simpleton and gives little value to the pipeline. The BNTX analyst sees the future more clearly - in my opinion.

Goldman has BNTX’s PT... https://t.co/9jF0PsfFuf

[Al Novas @AlNovas]

@BionTechPfizer and the market does nothing but reward MRNA vs BNTX. I am not seeing the rationale of of the market on this name over the past month. We are literally $215 below our share price when we released Q2 earnings. Our Q3 ... https://t.co/D1arw6VYpU